| Q89769453 | 18F-Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma as a Useful Predictor of an Extremely Rapid Response to Lenvatinib |
| Q52613914 | A Patient with HCV Infection and a Sustained Virological Response to Direct-acting Antiviral Treatment who Developed Inclusion Body Myositis. |
| Q44647941 | A Pilot Study of Thymosin .ALPHA.1 Therapy for Chronic Hepatitis B Patients |
| Q112564037 | A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis |
| Q35107005 | A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration |
| Q41642597 | A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection |
| Q53347425 | A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients. |
| Q42984537 | A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. |
| Q42283380 | A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C. |
| Q45163318 | Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus. |
| Q45174267 | Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C. |
| Q44744643 | Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus-related liver cancer. |
| Q91563510 | Advantage of liver stiffness measurement before and after direct-acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C |
| Q50088004 | Amino Acid Substitutions in the Hepatitis C Virus Core Region Predict Hepatocarcinogenesis Following Eradication of HCV RNA by All-Oral Direct-Acting Antiviral Regimens. |
| Q43034369 | Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment |
| Q50555852 | Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy. |
| Q42998703 | Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. |
| Q43036185 | Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy. |
| Q42983421 | Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy. |
| Q43039569 | Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. |
| Q42994827 | Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin. |
| Q42987024 | Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus. |
| Q42986911 | An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads. |
| Q36220756 | Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma. |
| Q46706535 | Anticarcinogenic impact of interferon on patients with chronic hepatitis C: a large-scale long-term study in a single center |
| Q43406355 | Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma |
| Q43186281 | Association of HLA-DR14 with the treatment response in Japanese patients with autoimmune hepatitis |
| Q42983726 | Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy. |
| Q42993815 | Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. |
| Q42990686 | Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 2a high viral load and virological response to interferon-ribavirin combination therapy. |
| Q43041835 | Association of amino acid substitution pattern in nonstructural protein 5A of hepatitis C virus genotype2a low viral load and response to interferon monotherapy. |
| Q42978588 | Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. |
| Q88052053 | Beneficial effect of arterial embolization with warmed miriplatin for multiple hepatocellular carcinoma |
| Q45163314 | Benefit of lamivudine therapy and factors associated with clinical outcome in spontaneous severe acute exacerbation of chronic hepatitis B virus infection |
| Q45390587 | Change of hepatitis B virus genotypes in acute and chronic infections in Japan |
| Q80489201 | Changes in viral loads of lamivudine-resistant mutants during entecavir therapy |
| Q41931003 | Cholangiolocellular Carcinoma in a Young Patient Who Showed Sustained Virological Response after Treatment for Hepatitis C Virus Infection |
| Q92466262 | Circulating MicroRNA-122 and Fibrosis Stage Predict Mortality of Japanese Patients With Histopathologically Confirmed NAFLD |
| Q59358936 | Circulating microRNA-122 levels are important predictor of hepatitis B virus surface antigen seroclearance |
| Q46501449 | Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study |
| Q80106408 | Clinical and pathological characteristics of the autoimmune hepatitis and primary biliary cirrhosis overlap syndrome |
| Q42989472 | Clinical and virological characteristics of untreated patients with chronic hepatitis C who develop serum alanine aminotransferase flare-up |
| Q43158113 | Clinical and virological effects of long-term (over 5 years) lamivudine therapy |
| Q45420743 | Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants |
| Q45733876 | Clinical characteristics of patients infected with hepatitis B virus genotypes A, B, and C. |
| Q39142527 | Clinical features of hepatitis B virus genotype A in Japanese patients. |
| Q44196875 | Clinicopathological features, background liver disease, and survival analysis of HCV-positive patients with hepatocellular carcinoma: differences between young and elderly patients |
| Q46978208 | Clinicopathological improvement of non-alcoholic steatohepatitis associated with weight loss during a 14-year follow-up period. |
| Q36359814 | Clinicopathological indices to predict hepatocellular carcinoma molecular classification |
| Q42985734 | Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load |
| Q33820376 | Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma |
| Q80559851 | Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B |
| Q42982320 | Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis |
| Q45728407 | Consistently low hepatitis B virus DNA saves patients from hepatocellular carcinogenesis in HBV-related cirrhosis. A nested case-control study using 96 untreated patients |
| Q42262670 | Correlation between hepatitis B virus surface antigen level and alpha-fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis |
| Q43269643 | Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment |
| Q64930871 | Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan. |
| Q81422871 | Cost-effectiveness of radiofrequency ablation and surgical therapy for small hepatocellular carcinoma of 3cm or less in diameter |
| Q89890136 | Detection of TERT promoter mutation in serum cell-free DNA using wild-type blocking PCR combined with Sanger sequencing in hepatocellular carcinoma |
| Q42980375 | Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1. |
| Q42995682 | Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection |
| Q45359335 | Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection. |
| Q43269644 | Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants. |
| Q45971639 | Development of hepatocellular carcinoma in elderly patients with chronic hepatitis C with or without elevated aspartate and alanine aminotransferase levels. |
| Q45363707 | Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy. |
| Q50558542 | Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients. |
| Q40207862 | Diabetes mellitus increases the risk of hepatocarcinogenesis in patients with alcoholic cirrhosis: A preliminary report. |
| Q81802242 | Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis |
| Q96683370 | Diagnosis and Resection Treatment of Triplet Hepatocellular Carcinomas with a non-B non-C Background in a Middle Aged Man over a Period of 6-years |
| Q82995276 | Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients |
| Q40051671 | Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma. |
| Q40363491 | Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis |
| Q42988882 | Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. |
| Q34499441 | Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma |
| Q42984530 | Effect of acute self-limited hepatitis C virus (HCV) superinfection on hepatitis B virus (HBV)-related cirrhosis. Virological features of HBV-HCV dual infection |
| Q43450451 | Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. |
| Q42244766 | Effectiveness and safety of reduced-dose telaprevir-based triple therapy in chronic hepatitis C patients |
| Q93384272 | Effectiveness of Particle Radiotherapy in Various Stages of Hepatocellular Carcinoma: A Pilot Study |
| Q33383219 | Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus-related cirrhosis and thrombocytopenia |
| Q41018829 | Effects of Alcohol Consumption on Hepatocarcinogenesis in Japanese Patients With Fatty Liver Disease |
| Q55296113 | Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies. |
| Q99559510 | Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver disease |
| Q99608239 | Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib |
| Q45402571 | Efficacy and anticarcinogenic activity of interferon for hepatitis C virus-related compensated cirrhosis in patients with genotype 1b low viral load or genotype 2. |
| Q42984851 | Efficacy and anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus-related compensated cirrhosis |
| Q45367944 | Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus. |
| Q46633267 | Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease. |
| Q42997469 | Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 1b and high virus load |
| Q42997474 | Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 2 and high virus load |
| Q43040948 | Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients. |
| Q59354247 | Efficacy and safety of elbasvir plus grazoprevir combination therapy in Japanese patients infected with hepatitis C virus genotype 1b |
| Q43046546 | Efficacy in patients with dose reduction in combination therapy of peginterferon and ribavirin for chronic hepatitis C. |
| Q45153982 | Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan. |
| Q46117660 | Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance? |
| Q45415178 | Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection. |
| Q43041127 | Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors |
| Q44920011 | Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy |
| Q42997762 | Efficacy of interferon therapy in elderly patients with chronic hepatitis C. |
| Q44516425 | Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. |
| Q80387916 | Efficacy of lamivudine therapy in elderly patients with chronic hepatitis B infection |
| Q45174261 | Efficacy of lamivudine treatment in Japanese patients with hepatitis B virus-related cirrhosis |
| Q40555175 | Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs |
| Q42979108 | Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy |
| Q46215715 | Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin |
| Q43049247 | Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load |
| Q50552096 | Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load. |
| Q45356302 | Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 2 and high virus load. |
| Q43024874 | Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients. |
| Q42991231 | Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1. |
| Q88495662 | Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b |
| Q40964348 | Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b. |
| Q45016760 | Evaluation of long-term biochemical responses to combination therapy of interferon plus ribavirin in those infected with hepatitis C virus genotype 1b and high baseline viral load. |
| Q41473188 | Evolution of simeprevir-resistant variants in virological non-responders infected with HCV genotype 1b. |
| Q42220429 | Evolution of simeprevir-resistant variants over time by ultra-deep sequencing in HCV genotype 1b. |
| Q50550265 | Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients. |
| Q42995163 | Extending combination therapy with peginterferon plus ribavirin for genotype 2 chronic hepatitis C virological responders: a pilot study of 7 cases |
| Q45403562 | Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine. |
| Q45006616 | Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. |
| Q40473920 | Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older. |
| Q59354868 | Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-acting antivirals regimens |
| Q45268137 | Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study. |
| Q96343881 | Fulminant Hepatitis due to de novo Hepatitis B after Cord Blood Transplantation Rescued by Medical Treatment |
| Q34235518 | Gene expression in fixed tissues and outcome in hepatocellular carcinoma. |
| Q42907651 | HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy |
| Q44453942 | HBe antigen loss during lamivudine therapy is not caused by mutations in precore and core promoter genes in patients with chronic hepatitis B. |
| Q42201273 | HLA-DP genes polymorphisms associate with hepatitis B surface antigen kinetics and seroclearance during nucleot(s)ide analogue therapy. |
| Q45492244 | Hepatitis B virus-related hepatocellular carcinogenesis and its prevention |
| Q37362701 | Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis |
| Q44526937 | Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients. |
| Q80287543 | Hepatocellular carcinoma in noncirrhotic young adult patients with chronic hepatitis B viral infection |
| Q58605343 | Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan |
| Q42990767 | Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis |
| Q84975066 | Heterogeneous type 4 enhancement of hepatocellular carcinoma on dynamic CT is associated with tumor recurrence after radiofrequency ablation |
| Q83131613 | High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma |
| Q42984269 | High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load. |
| Q34631965 | Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively. |
| Q44516422 | Histological improvements after a three-year lamivudine therapy in patients with chronic hepatitis B in whom YMDD mutants did not or did develop |
| Q35968616 | Impact of Mutations at Amino Acid 70 in Hepatitis C Virus (HCV) Genotype 1b Core Region on Hepatocarcinogenesis following Eradication of HCV RNA. |
| Q40802631 | Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan |
| Q91134471 | Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues |
| Q90704076 | Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus |
| Q42260234 | Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis C. |
| Q45547176 | Infection with hepatitis B virus genotype A in Tokyo, Japan during 1976 through 2001. |
| Q50557485 | Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. |
| Q42993090 | Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b. |
| Q43039256 | Influence of hepatitis C virus subtype on hepatocellular carcinogenesis: a multivariate analysis of a retrospective cohort of 593 patients with cirrhosis |
| Q43046743 | Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus |
| Q92566741 | Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections |
| Q36547263 | Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma |
| Q44250044 | Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy |
| Q45407427 | Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis. |
| Q42987233 | Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment. |
| Q42989123 | Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection. |
| Q43047009 | Interferon-alpha for reinfection with hepatitis C virus in two patients with chronic hepatitis C who had responded to previous therapies |
| Q45401072 | Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection. |
| Q44043595 | Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B. |
| Q33397694 | Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma |
| Q40375140 | Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens. |
| Q50455127 | Lipiodol and dye at the site of ablation decreases during RFA. |
| Q40557264 | Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals. |
| Q40782607 | Long-Term Outcomes of Hepatitis-C-Infected Patients Achieving a Sustained Virological Response and Undergoing Radical Treatment for Hepatocellular Carcinoma |
| Q45713237 | Long-term clinical remission induced by corticosteroid withdrawal therapy (CSWT) in patients with chronic hepatitis B infection: a prospective randomized controlled trial--CSWT with and without follow-up interferon-alpha therapy |
| Q84280056 | Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients |
| Q36401963 | Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection. |
| Q42278002 | Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine |
| Q45359396 | Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan. |
| Q44323346 | Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection |
| Q80154191 | Long-term follow-up of HBeAg-positive young adult Japanese patients treated with corticosteroid withdrawal therapy for chronic hepatitis B |
| Q45434601 | Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival |
| Q42981430 | Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma |
| Q46907493 | Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. |
| Q43034408 | Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. |
| Q40274896 | Long-term outcome of HBV carriers with negative HBe antigen and normal aminotransferase. |
| Q59354057 | Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan |
| Q92361488 | Long-term outcome of hepatocellular carcinoma occurrence, esophageal varices exacerbation, and mortality in hepatitis C virus-related liver cirrhosis after interferon-based therapy |
| Q54559601 | Long-term presence of HBV in the sera of chronic hepatitis B patients with HBsAg seroclearance. |
| Q39400111 | Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis -- an open-cohort study |
| Q45923422 | Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C. |
| Q80809561 | Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine |
| Q44759054 | Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine. |
| Q46629124 | Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up |
| Q48508898 | Magnetic resonance laparoscopy: A new non-invasive technique for the assessment of chronic viral liver disease |
| Q94603188 | Microvascular Invasion and a Size Cutoff Value of 2 cm Predict Long-Term Oncological Outcome in Multiple Hepatocellular Carcinoma: Reappraisal of the American Joint Committee on Cancer Staging System and Validation Using the Surveillance, Epidemiolo |
| Q38726399 | Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition |
| Q44225016 | Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy |
| Q42998329 | Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections. |
| Q42982755 | Natural human interferon beta plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus and a high viral load |
| Q42986943 | Necessities of interferon therapy in elderly patients with chronic hepatitis C. |
| Q38720197 | New Discriminant Method for Identifying the Aggressive Disease Phenotype of Non-alcoholic Fatty Liver Disease |
| Q46902240 | New ablation procedure for a radiofrequency liver tissue coagulation system using an expandable needle. |
| Q85120340 | New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma |
| Q35289022 | New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan |
| Q57046246 | No-touch ablation in HCC has the potential to prevent intrasubsegmental recurrence to the same degree as surgical resection |
| Q101224106 | Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease |
| Q91840506 | Optimal management of patients with hepatocellular carcinoma treated with lenvatinib |
| Q39755582 | Origin of neovascular structure in an early stage of hepatocellular carcinoma: study of alpha-smooth muscle actin immunohistochemistry in serial thin sections of surgically resected cancer |
| Q33441426 | Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease |
| Q80415474 | Peripheral CD8+/CD25+ lymphocytes may be implicated in hepatocellular injuries in patients with acute-onset autoimmune hepatitis |
| Q39711195 | Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan |
| Q97893191 | Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma |
| Q90324902 | Platelet-Albumin Score as a Sensitive Measure for Surgical Risk Prediction and Survival Outcomes of Patients with Hepatocellular Carcinoma |
| Q42982601 | Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads |
| Q90753854 | Poorly Differentiated Hepatocellular Carcinoma in a Low-risk Patient with an Otherwise Normal Liver |
| Q42627754 | Portal vein thrombosis in liver cirrhosis: incidence, management, and outcome. |
| Q102149478 | Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment |
| Q86489475 | Potential of a no-touch pincer ablation procedure for small hepatocellular carcinoma that uses a multipolar radiofrequency ablation system: An experimental animal study |
| Q51097786 | Potential of a no-touch pincer ablation procedure that uses a multipolar radiofrequency ablation system to prevent intrasubsegmental recurrence of small and single hepatocellular carcinomas. |
| Q37174808 | Potential of laparoscopy in chronic liver disease with hepatitis B and C viruses |
| Q104058657 | Potential of ultra-highly sensitive immunoassays for hepatitis B surface and core-related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen seroclearance |
| Q45722551 | Precore wild-type hepatitis B virus with G1896 in the resolution of persistent hepatitis B virus infection. |
| Q45417617 | Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts |
| Q43040333 | Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. |
| Q37125066 | Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with hepatitis C virus genotype 1. |
| Q82661340 | Predictive factors of advanced recurrence after curative resection of small hepatocellular carcinoma |
| Q43033968 | Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholest |
| Q42996720 | Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. |
| Q90167983 | Predictors of Insulin Secretion in Japanese Patients with Histopathologically-confirmed Non-alcoholic Fatty Liver Disease |
| Q40283352 | Predictors of pruritus in patients with chronic liver disease and usefulness of nalfurafine hydrochloride |
| Q48282855 | Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2. |
| Q43040673 | Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. |
| Q97543793 | Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis |
| Q43671045 | Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of <126 mg/dL. |
| Q34638767 | Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. |
| Q42212826 | Prevention of disease progression with anti-inflammatory therapy in patients with HCV-related cirrhosis: a Markov model. |
| Q51024778 | Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma. |
| Q90407027 | Primary liver carcinoma with sarcomatous changes: Analysis of 10 cases |
| Q40138677 | Prognosis and predictors of hepatocellular carcinoma in elderly patients infected with hepatitis B virus. |
| Q45399153 | Prolonged hepatitis after acute infection with genotype H hepatitis B virus |
| Q46608575 | Prolonged-efficacy of bisphosphonate in postmenopausal women with osteoporosis and chronic liver disease. |
| Q50571468 | Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C. |
| Q91264453 | REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset |
| Q53020571 | Randomized Controlled Trial Comparing the Efficacy of Impedance Control and Temperature Control of Radiofrequency Interstitial Thermal Ablation for Treating Small Hepatocellular Carcinoma. |
| Q79929959 | Randomized controlled trial for the efficacy of hepatic arterial occlusion during radiofrequency ablation for small hepatocellular carcinoma--direct ablative effects and a long-term outcome |
| Q85828089 | Randomized controlled trial of a new procedure of radiofrequency ablation using an expandable needle for hepatocellular carcinoma |
| Q45725112 | Randomized trial of prolonged interferon retreatment for chronic hepatitis C patients with HCV-genotype 1b and high virus load |
| Q43771522 | Randomized, controlled trial of natural interferon-alpha therapy for e-antigen-positive chronic hepatitis B patients |
| Q113702826 | Rapid and high sensitive detection of Y93H amino acid substitution in HCV NS5A region using the PCR-Invader assay |
| Q45382693 | Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks. |
| Q92198449 | Real-world effects of long-term rifaximin treatment for Japanese patients with hepatic encephalopathy |
| Q42981728 | Recurrence rate and prognosis of patients with hepatocellular carcinoma that developed after elimination of hepatitis C virus RNA by interferon therapy. A closed cohort study including matched control patients |
| Q88224893 | Recurrence rates of pruritus after the stop of nalfurafine hydrochloride in chronic liver disease: Preliminary prospective confirmatory trial |
| Q36848963 | Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan |
| Q41041935 | Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. |
| Q86483796 | Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B |
| Q39766568 | Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C. |
| Q40631323 | Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan. |
| Q92616126 | Role of NS5A-L31/Y93 Double Wild-type in Failure of Glecaprevir/Pibrentasvir Double Therapy in Two Patients with a History of Direct-acting Antiviral Agent Failure: An Ultra-deep Sequencing Analysis |
| Q95654740 | SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology |
| Q45405023 | Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H. |
| Q40041670 | Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b. |
| Q51217648 | Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up. |
| Q50571192 | Serum KL-6 level is elevated in chronic hepatitis C patients with combination therapy of pegylated interferon and ribavirin. |
| Q45728706 | Serum levels of gamma-globulin and total bilirubin influence the prevalence of multiple extrahepatic complication in patients with hepatitis C virus infection |
| Q44813425 | Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B. |
| Q50569792 | Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C. |
| Q45532567 | Significance of hepatitis B virus DNA clearance and early prediction of hepatocellular carcinogenesis in patients with cirrhosis undergoing interferon therapy: long-term follow up of a pilot study |
| Q45274608 | Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma: a longterm cohort study of 892 patients with viral cirrhosis. |
| Q50579279 | Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C. |
| Q43801035 | Stage progression of small hepatocellular carcinoma after radical therapy: comparisons of radiofrequency ablation and surgery using the Markov model |
| Q96956734 | Steatohepatitic Variant of Hepatocellular Carcinoma Is Associated With Both Alcoholic Steatohepatitis and Nonalcoholic Steatohepatitis: A Study of 2 Cohorts With Molecular Insights |
| Q74806346 | Stepwise hook extension technique for radiofrequency ablation therapy of hepatocellular carcinoma |
| Q42979100 | Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma |
| Q53626434 | Successful control of ruptured hepatocellular carcinoma with radiofrequency ablation. |
| Q50568065 | Suitable treatment period in patients with virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C. |
| Q42984064 | Sustained negativity for HCV-RNA over 24 or more months by long-term interferon therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load |
| Q39483711 | Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. |
| Q42992119 | Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir |
| Q42984313 | Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. |
| Q100392307 | TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease |
| Q91867490 | The Lack of Hepatocyte Steatosis in Adult-onset Type II Citrullinemia Patients as Assessed by 7-year Interval Paired Biopsies |
| Q58088666 | The complex association of virus- and host-related factors with HCC rate following HCV clearance |
| Q51164094 | The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease. |
| Q40340001 | The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings |
| Q42982091 | The efficacy of 24-week interferon monotherapy for type C liver cirrhosis in Japanese patients with genotype 1b and low virus load |
| Q51619721 | The efficacy of interferon-beta monotherapy for elderly patients with type C hepatitis of genotype 2. |
| Q43046524 | The efficacy of short-term interferon-beta therapy for chronic hepatitis C patients with low virus load |
| Q42979133 | The efficacy of short-term interferon-beta therapy for type C cirrhotic patients with genotype 2a and low virus load. |
| Q40605234 | The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. |
| Q45853525 | Therapeutic effects of short- and intermediate-term tolvaptan administration for refractory ascites in patients with advanced liver cirrhosis |
| Q39916255 | Three-Dimensional Imaging Using Contrast-Enhanced and Three-Dimensional Ultrasound Techniques in the Ablative Zone Treated with a Multipolar Radiofrequency Ablation System for Hepatocellular Carcinoma. |
| Q40706953 | Three-dimensional magnetic resonance imaging for stringent diagnosis of advanced fibrosis associated with nonalcoholic steatohepatitis. |
| Q92692034 | Time-to-Interventional Failure as a New Surrogate Measure for Survival Outcomes after Resection of Hepatocellular Carcinoma |
| Q40300538 | Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma. |
| Q36715169 | Transcatheter arterial chemotherapy with miriplatin for hepatocellular carcinoma patients with chronic renal failure: report of three cases |
| Q43048434 | Type C-chronic hepatitis patients who had autoimmune phenomenon and developed jaundice during interferon therapy |
| Q97534992 | Undifferentiated carcinoma of the liver demonstrated by contrast-enhanced ultrasonography |
| Q89343949 | Usefulness and limitations of balloon-occluded transcatheter arterial chemoembolization using miriplatin for patients with four or fewer hepatocellular carcinoma nodules |
| Q40555460 | Usefulness of serum KL-6 for early diagnosis of idiopathic pulmonary fibrosis in patients with hepatitis C virus. |
| Q45435671 | Usefulness of the serum KL-6 assay in patients with hepatitis C virus |
| Q37546699 | Utility of detection of telaprevir-resistant variants for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection |
| Q43037393 | Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load |
| Q51110886 | Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. |
| Q44177457 | Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan |
| Q33857643 | Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir |
| Q42988811 | Virological and biochemical features in elderly HCV patients with hepatocellular carcinoma: amino acid substitutions in HCV core region as predictor of mortality after first treatment. |
| Q40556453 | Virological and biochemical relapse according to YMDD motif mutant type during long‐term lamivudine monotherapy |
| Q46423677 | Virological and biochemical relapse after discontinuation of lamivudine monotherapy for chronic hepatitis B in Japan: comparison with breakthrough hepatitis during long-term treatment |
| Q45480055 | Virological differences between patients infected with subtypes Ba and Bj of hepatitis B virus genotype B. |
| Q45422348 | Virological outcomes in patients infected chronically with hepatitis B virus genotype A in comparison with genotypes B and C. |
| Q43762472 | Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil. |
| Q42994183 | Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus. |
| Q37196482 | What Is the Most Effective Drug Delivery System for Cisplatin during the Treatment of Hepatic Tumors with Single-Session Transcatheter Chemotherapy? A Pilot Study |
| Q45032979 | YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine |
| Q52395592 | [Transcatheter arterial chemotherapy with miriplatin for patients with hepatocellular carcinoma and chronic renal failure]. |